Improving Pain Treatment Outcomes
Genetic testing is used to identify a patient’s risk for tolerance, dependence, or abuse to medications, how they will metabolize their medications, and whether they are ultimately complying with therapy. Used in combination with urine drug screens for on-going patient medication monitoring, genetic testing is a valuable tool for patient pain treatment.
Samia Solutions has partnered with a leading provider of proprietary laboratory testing to improve the selection, dosing, and evaluation of pain medications. This testing helps doctors protect patients from the costly epidemic of prescription pain medication abuse and helps doctors prescribe the best medication for each patient. Samples are easily obtained in-office with a needle-less, blood-less, painless cheek swab (buccal cells) and then sent to a high-complexity, CLIA-certified laboratory for testing. Reports are comprehensive yet enable a physician to easily interpret results for effective patient treatment.
There is increasing support for genetic testing. The American College of Occupational and Environmental Medicine (ACOEM) Guidelines support genetic testing “when it is clear that the genetic trait directly affects job performance, when the trait being screened for predisposes a worker to a significant, consistent adverse outcome following an otherwise acceptable workplace exposure.” Further, ACOEM Guidelines for Chronic Use of Opioids (2011) state: “there is a significant risk of substance abuse, addiction, and diversion related to genetic factors” and “screening for risk of addiction should be performed before starting a long-term opioid treatment in patients with chronic pain, thus providing the physician with clues about the necessity for increased attention in susceptible patients. If opioid treatment results in pain control, better functioning and improved health related quality of life the treatment should of course be continued, even in patients susceptible for addiction.”
Narcotic Risk Assessment
According to the American Society of Addictive Medicine, an imbalance in brain chemicals predisposes a patient for abuse, tolerance, or physical dependence. Three times more people are addicted to and die from prescription narcotic pain medications than all illegal narcotics combined. The burden of this horrible epidemic is costing the healthcare system immensely, with chronic pain now costing over $558 Billion annually.
A Narcotic Risk Assessment is a proprietary genetic test evaluating a panel of 12-genes to analyze patient risk for Rx pain medication tolerance, dependence or abuse. According to the National Institutes of Drug Abuse and the American Society of Addictive Medicine, up to 60% of substance abuse is due to genetic factors. This proprietary narcotic risk assessment will assist a physician in determining a patient’s potential genetic risk.
The Narcotic Risk Assessment can help a prescriber better determine the course of pain management therapy. On-going patient care, including the use of urine drug screening to monitor patient medication intake, when combined with these findings allow for more effective treatment.
Drug Metabolism Assessment
60% of patients are unable to control their pain with current medications. This leads to physicians prescribing higher doses, greater potency, and more powerful medications. A physician can utilize a proprietary genetic test with a panel of up to 64 genetic assessments to evaluate predisposed liver metabolism of most medications. Physicians can improve drug selection and dosing, as well as better interpret urine drug testing results with the use of this drug metabolism test.
With most pain patients unable to control their pain, doctors are confronted with the challenge of finding the most effective and safest medications for their patients. Over 80% of prescription and over-the-counter medications are metabolized hepatically, and close to 50% of Americans have a genetic predisposition altering their normal metabolism of prescription pain medications . The inability to control pain with current therapies has led to a dramatic escalation in pharmacy costs as doctors “chase failure” with more dose, potency, and additional medications.
The Drug Metabolism Assessment will allow a prescriber can better understand which drugs or how much of a medication is more likely to be effective, as well as better understand the results of urine drug monitoring test results.
Samia Solutions’ program has numerous benefits for a physician and patients, including:
- Easy for the Patient – A pain-free, needle-free, blood-free cheek swab (buccal cells) is administered and then sent to a high-complexity, CLIA-certified laboratory for testing
- Easy for the Physician and Practice – Staff trained to collect patient specimens in the office and on-going support provided by Samia Solutions
- Comprehensive Reporting – Detailed reports are provided to physicians in an easily interpreted format. Reports from laboratory provided back to the practice within 7 to 10 business days
- Genetic Testing Study – Provider can opt to participate in a study regarding the genetic testing program
- Payor Acceptance – Covered by many workers compensation carriers and some private insurance payors with additional payors anticipated in the immediate future